Protocol Name: A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure.
Sponsor: AstraZeneca
Indication: CKD & HTN
GFR: 30-89
Principal Investigator: Ankit Mehta, MD
Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246